SWOG clinical trial number
SWOG-8947
Central Lymphoma Serum Repository Protocol
Closed
Phase
Research committees
Lymphoma
Eligibility Criteria Expand/Collapse
For patients registered to a currently active Southwest Oncology Group-coordinated treatment protocol for previously untreated non-Hodgkin's lymphoma.
Publication Information Expand/Collapse
2015
PMid: PMID25823738 | PMC number: PMC4404425
Other Clinical Trials
SWOG Clinical Trial Number
CTSU/EA4232
A Randomized Phase III Study to Evaluate Benefits of Autologous Stem Cell Transplant in Patients with Peripheral T Cell Lymphoma That Achieved a First Complete Remission (CR1) Following Induction Therapy (PTCL-STAT)
Research Committee(s)
Lymphoma
Activated
01/30/2025
Open
Phase
SWOG Clinical Trial Number
S2308
Randomized Phase III Study of Mosunetuzumab vs. Rituximab for Low Tumor Burden Follicular Lymphoma
Research Committee(s)
Lymphoma
Activated
08/01/2024
Accrual
37%
Open
Phase
SWOG Clinical Trial Number
S2207
Randomized Phase II Study of the Addition of Targeted Therapeutic Agents to Tafasitamab-Based Therapy in Non-Transplant-Eligible Patients with Relapse/Refractory Large B-Cell Lymphoma
Research Committee(s)
Lymphoma
Activated
06/30/2023
Accrual
14%
Open
Phase